Our Story
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Our primary goal is to facilitate the success of companies in our areas of focus through early to expansion stage investments and value-adding resources.
Our Team
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe.
News
Aileron Aquires ABC Company
January 23rd 2010
Aileron Therapeutics, Inc.
Aileron is developing a technology termed Stapled Peptides, in which short peptide sequences corresponding to an alpha-helix of a protein are stabilized using a synthetic bridge.
Second News Item
January 23rd 2010
Aileron Therapeutics, Inc.
Aileron is developing a technology termed Stapled Peptides, in which short peptide sequences corresponding to an alpha-helix of a protein are stabilized using a synthetic bridge. Aileron is developing a technology termed Stapled Peptides, in which short peptide sequences corresponding to an alpha-helix of a protein are stabilized using a synthetic bridge.
Third News Item
January 23rd 2010
Aileron Therapeutics, Inc.
Aileron is developing a technology termed Stapled Peptides, in which short peptide sequences corresponding to an alpha-helix of a protein are stabilized using a synthetic bridge.
Fourth News Item
January 23rd 2010
Aileron Therapeutics, Inc.
Aileron is developing a technology termed Stapled Peptides, in which short peptide sequences corresponding to an alpha-helix of a protein are stabilized using a synthetic bridge. Aileron is developing a technology termed Stapled Peptides, in which short peptide sequences corresponding to an alpha-helix of a protein are stabilized using a synthetic bridge.